

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/913,329	08/21/2001	Luc Desgroseillers	163-34	8479
23117 7	590 11/03/2004		EXAM	INER
NIXON & VANDERHYE, PC 1100 N GLEBE ROAD			PAK, YONG D	
8TH FLOOR			ART UNIT	PAPER NUMBER
ARLINGTON, VA 22201-4714			1652	

DATE MAILED: 11/03/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/913,329	DESGROSEILLERS ET AL.			
Office Action Summary	Examiner	Art Unit			
	Yong D Pak	1652			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPL' THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a repl' - If NO period for reply is specified above, the maximum statutory period of the specified above, the specif	36(a). In no event, however, may a reply within the statutory minimum of thirty (3 will apply and will expire SIX (6) MONTH cause the application to become ARAN	y be timely filed 30) days will be considered timely. IS from the mailing date of this communication.			
Status					
1) Responsive to communication(s) filed on 10 S	eptember 2004.				
2a)☐ This action is FINAL . 2b)⊠ This	action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) ⊠ Claim(s) 41-43 and 47-49 is/are pending in the 4a) Of the above claim(s) is/are withdraw 5) ⊠ Claim(s) 47 is/are allowed. 6) ⊠ Claim(s) 41-43 and 47-49 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or	vn from consideration.				
Application Papers 9)☐ The specification is objected to by the Examiner					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119	ammer. Note the attached O	Tilice Action or form PTO-152.			
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview Sumr	mary (PTO-413)			
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Ma	ail Date´. nal Patent Application (PTO-152)			

Art Unit: 1652

DETAILED ACTION

The after final amendment filed on September 10, 2004, amending claims 41 and 47 and canceling claims 1-13, 15-28, 30-40, 44-46 and 50-61, has been entered.

Response to Arguments

In view of the amendment filed on September 10, 2004, PROSECUTION IS HEREBY REOPENED. A new rejection is set forth below.

To avoid abandonment of the application, appellant must exercise one of the following two options:

- (1) file a reply under 37 CFR 1.111 (if this Office action is non-final) or a reply under 37 CFR 1.113 (if this Office action is final); or,
 - (2) request reinstatement of the appeal.

If reinstatement of the appeal is requested, such request must be accompanied by a supplemental appeal brief, but no new amendments, affidavits (37 CFR 1.130, 1.131 or 1.132) or other evidence are permitted. See 37 CFR 1.193(b)(2).

Rejections and/or objections not reiterated from previous office actions are hereby withdrawn

Allowable Subject Matter

The indicated allowability of claims 41-43 and 48-49 are withdrawn in view of the new rejection set forth below. Claim 47 remains allowed.

Art Unit: 1652

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 41-43 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a metallopeptidase of SEQ ID NO:13, does not reasonably provide enablement for a metallopeptidase variant having 77% sequence identity to SEQ ID NO:13. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Factors to be considered in determining whether undue experimentation is required are summarized in <u>In re Wands 858 F.2d 731, 8 USPQ2nd 1400 (Fed. Cir.</u> 1988). They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.

The claims are drawn to a metallopeptidase variant of SEQ ID NO:13. The specification does not teach which 23% of the structure SEQ ID NO:13 can be modified. Therefore, these claims are drawn to a genus of polypeptides having undefined structure.

Art Unit: 1652

The scope of the claims is not commensurate with the enablement provided by the disclosure with regard to the extremely large number of polypeptides encompassed by the claims. Since the amino acid sequence of a protein determines its structural and functional properties, predictability of which changes can be tolerated in a protein's amino acid sequence and obtain the desired activity requires a knowledge of and guidance with regard to which amino acids in the protein's sequence, if any, are tolerant of modification and which are conserved (i.e. expectedly intolerant to modification), and detailed knowledge of the ways in which the proteins' structure relates to its function. However, in this case the disclosure is limited to the polypeptides comprising SEQ ID NO: 13.

It would require undue experimentation of the skilled artisan to make and use the claimed polypeptides. The specification is limited to teaching the use of the polypeptides of SEQ ID NO:13 but provides no guidance with regard to the making of other variants and mutants or with regard to other uses. In view of the great breadth of the claim, amount of experimentation required to make the claimed polypeptides, the lack of guidance, working examples, and unpredictability of the art in predicting function from a polypeptide primary structure, the claimed invention would require undue experimentation. As such, the specification fails to teach one of ordinary skill how to use the full scope of the polypeptides encompassed by the claims.

While enzyme isolation techniques, recombinant and mutagenesis techniques are known, and it is routine in the art to screen for multiple substitutions or multiple modifications as encompassed by the instant claims, the specific amino acid positions

Art Unit: 1652

within a protein's sequence where amino acid modifications can be made with a reasonable expectation of success in obtaining the desired activity/utility are limited in any protein and the result of such modifications is unpredictable. In addition, one skilled in the art would expect any tolerance to modification for a given protein to diminish with each further and additional modification, e.g. multiple substitutions.

The specification does not support the broad scope of the claims which encompass all modifications and variants of a metallopeptidase of SEQ ID NO:13 because the specification does not establish: (A) regions of the polypeptide structure which may be modified without affecting metallopeptidase activity; (B) the general tolerance of metallopeptidase to modification and extent of such tolerance; (C) a rational and predictable scheme for modifying any amino acid residue with an expectation of obtaining the desired biological function; and (D) the specification provides insufficient guidance as to which of the essentially infinite possible choices is likely to be successful.

Thus, applicants have not provided sufficient guidance to enable one of ordinary skill in the art to make and use the claimed invention in a manner reasonably correlated with the scope of the claims broadly including metallopeptidases with an enormous number of amino acid modifications of the metallopeptidase of SEQ ID NO: 13. The scope of the claims must bear a reasonable correlation with the scope of enablement (*In re Fisher*, 166 USPQ 19 24 (CCPA 1970)). Without sufficient guidance, determination of the metallopeptidase variant structure having catalytic activity is unpredictable and the experimentation left to those skilled in the art is unnecessarily,

Art Unit: 1652

and improperly, extensive and undue. See *In re Wands* 858 F.2d 731, 8 USPQ2nd 1400 (Fed. Cir, 1988).

See In re Wands 858 F.2d 731, 8 USPQ2nd 1400 (Fed. Cir, 1988).

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 42 and 48 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claims 42 and 48, the article in front of "isolated nucleotide sequence of claim 41" should recite "the" so that the claim clearly recites the nucleotide sequence of claim 41 or 47.

Claims 43 and 49 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

In claims 43 and 49, the phrase "capable of expressing a metallopeptidase, polypeptide or part thereof" is unclear. The metes and bounds of the phrase in the context of the above claim is not clear to the Examiner. Therefore the claims are indefinite.

Art Unit: 1652

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong Pak whose telephone number is 571-272-0935. The examiner can normally be reached 6:30 A.M. to 5:00 P.M. Monday through Thursday.

Page 7

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

Yong D. Pak
Patent Examiner